Market revenue in 2023 | USD 1,978.5 million |
Market revenue in 2030 | USD 2,095.2 million |
Growth rate | 0.8% (CAGR from 2023 to 2030) |
Largest segment | Antacids |
Fastest growing segment | H2 Receptor Blockers |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents |
Key market players worldwide | AstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.
Antacids was the largest segment with a revenue share of 56.66% in 2023. Horizon Databook has segmented the North America gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.
The rise in incidence of GERD in North America is responsible for increase in demand for acid reducing and neutralizing drugs. In addition, the self-medication trend for management of digestive and gastrointestinal disorders has become popular, owing to convenience, time saved, and cost-effectiveness.
Based on a study published by National Center for Biotechnology Information (NCBI) in the year 2014, the prevalence GERD in North America ranges between 18% and 28%. Rise in initiatives for creating awareness and educating people is expected to boost the regional market.
For instance, the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) foundation promotes awareness, education, and research on reflux and GERD.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account